ReviewNature reviews. Clinical oncology2025
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy.
Review in Nature reviews. Clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Spatiotemporal heterogeneity in non-small cell lung cancer: A paradigm shift from characterization to dynamic management (Review).Oncology letters · 2026Review
- Innate Immune Cells in Non-Small Cell Lung Cancer: Roles in Tumor Progression and Therapeutic Responses.Cancer innovation · 2026Review
- Research trends in cytokine regulation of immunotherapy in non-small cell lung cancer: a bibliometric and BERTopic analysis from 2015 to 2025.Journal of thoracic disease · 2026Article
- Specific PET Imaging for Precision Management of Lung Cancer: Advances, Clinical Translation and Future Directions.Chemical & biomedical imaging · 2026Review
- Prolactin as a Candidate Biomarker in Non-Small Cell Lung Cancer: Implications for Personalized Medicine and Post-Treatment Risk Stratification.Journal of personalized medicine · 2026Review
- Review
- Ceramide signaling in non-small-cell lung cancer: from dysregulation to targeted therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Ginsenoside Rh2 inhibits non-small-cell lung cancer malignant progression through targeting AURKA.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- cGAS-STING pathway regulated by spatiotemporal heterogeneity of tumor microenvironment and precision therapy strategies in lung cancer.Journal of experimental & clinical cancer research : CR · 2026Review
- Autophagy-Apoptosis Crosstalk in Cancer: Mechanisms, Signaling Pathways, and Therapeutic Targeting.Cancers · 2026Review
- Ferroptosis-related lncRNA signature predicts prognosis and treatment response in colon cancer.Translational cancer research · 2026Article
- Immune Aging Within the Tumor Microenvironment Predicts Survival in Lung Adenocarcinoma.Cancers · 2026Article
- EBF3 suppresses lung adenocarcinoma progression and immune evasion via transcriptional repression of CCL24.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Therapy-induced remodeling of the tumor immune microenvironment: Mechanistic insights and implications for immunotherapy.Chinese medical journal · 2026Review
- Article
- Hyperprogressive disease in carcinoma induced by immune checkpoint inhibitor therapy: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- IL‑6: A key player in the EGFR‑TKI‑resistant tumor microenvironment and its therapeutic implications (Review).International journal of oncology · 2026Review
- Anoikis-Related Genes Signature Contributes to Predicting Prognosis and Response to Immunotherapy in Lung Squamous Cell Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Mast cell-derived MIF Polarizes Th17 cells to drive lung adenocarcinoma progression.Cancer immunology, immunotherapy : CII · 2026Article
- Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The treatment landscape of non-small-cell lung cancer (NSCLC) is evolving rapidly, driven by advances in the development of targeted agents and immunotherapies. Despite this progress, some patients have suboptimal responses to treatment, highlighting the need for new therapeutic strategies. In the past decade, the important role of the tumour microenvironment (TME) in NSCLC progression, metastatic dissemination and response to treatment has become increasingly evident. Understanding the complexity of the TME and its interactions with NSCLC can propel efforts to improve current treatment modalities, overcome resistance and develop new treatments, which will ultimately improve the outcomes of patients. In this Review, we provide a comprehensive view of the NSCLC TME, examining its components and highlighting distinct archetypes characterized by spatial niches within and surrounding tumour nests, which form complex neighbourhoods. Next, we explore the interactions within these components, focusing on how inflammation and immunosuppression shape the dynamics of the NSCLC TME. We also address the emerging influences of patient-related factors, such as ageing, sex and health disparities, on the NSCLC-TME crosstalk. Finally, we discuss how various therapeutic strategies interact with and are influenced by the TME in NSCLC. Overall, we emphasize the interconnectedness of these elements and how they influence therapeutic outcomes and tumour progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.